Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.

Frontiers in Pharmacology
Roberta RobertiRita Citraro

Abstract

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to prevent and treat venous thromboembolism. Despite their widespread use in clinical practice, there are still some unresolved issues on optimizing their use in particular clinical settings. Herein, we reviewed the current clinical evidence on uses of DOACs from pharmacology and clinical indications to safety and practical issues such as drugs and food interactions. Dabigatran is the DOAC most affected by interactions with drugs and food, although all DOACs demonstrate a favorable pharmacokinetic profile. Management issues associated with perioperative procedures, bleeding treatment, and special populations (pregnancy, renal and hepatic impairment, elderly, and oncologic patients) have been discussed. Literature evidence shows that DOACs are at least as effective as VKAs, with a favorable safety profile; data are particularly encouraging in using low doses of edoxaban in elderly patients, and edoxaban and rivaroxaban in the treatment of venous thromboembolism in oncologic patients. In the next year, DOAC clinical indications are likely to be further extended.

References

Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
Sep 27, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Steven R DeitcherUNKNOWN ONCENOX Investigators
Dec 6, 2006·The American Journal of Medicine·Russell D HullUNKNOWN LITE Trial Investigators
Nov 17, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechWilly Roth
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Feb 7, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·C WeinzD Lang
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Nov 26, 2009·Patient Preference and Adherence·L BellamyBi Eriksson
Feb 15, 2011·Journal of Thrombosis and Thrombolysis·Pancras C WongDonglu Zhang
Apr 26, 2011·The Journal of Pharmacology and Experimental Therapeutics·Mark Jean GnothSteffen Sandmann
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Mar 6, 2013·International Journal of Clinical Pharmacology and Therapeutics·Jan StampfussWolfgang Mueck
Apr 9, 2013·Journal of the American College of Cardiology·Jeffrey D WesslerRobert P Giugliano
Apr 30, 2013·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Hein HeidbuchelUNKNOWN European Heart Rhythm Association
Aug 21, 2013·Best Practice & Research. Clinical Haematology·Stefano BarcoMichiel Coppens
Nov 14, 2013·Current Clinical Pharmacology·Reinhold Kreutz
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Jan 24, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Yishen Wang, Beata Bajorek
Mar 13, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Anna Plitt, Robert P Giugliano
Jul 19, 2014·Drugs·Henri Bounameaux, A John Camm
Nov 6, 2014·The New England Journal of Medicine·Jack E AnsellJames C Costin
Mar 31, 2015·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Andres EnriquezAdrian Baranchuk
Jun 13, 2015·Clinical Drug Investigation·Jeanne MendellDolly A Parasramupria
Jun 23, 2015·The New England Journal of Medicine·Charles V PollackJeffrey I Weitz
Jul 15, 2015·American Journal of Obstetrics and Gynecology·Priya BapatGideon Koren
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Agnes Y Y LeeUNKNOWN CATCH Investigators
Sep 12, 2015·Journal of Clinical Pharmacology·Ming ChangCharles E Frost
May 6, 2016·Journal of Thrombosis and Haemostasis : JTH·P BapatS Ito
May 22, 2016·Journal of the American Heart Association·Eri Toda KatoElliott M Antman

❮ Previous
Next ❯

Software Mentioned

ARISTOTELE
SELECT

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.